Diflomotecan

From Wikipedia, the free encyclopedia
Diflomotecan
Diflomotecan.png
Clinical data
Trade namesDiflomotecan
Identifiers
  • (R)-5-ethyl-9,10-difluoro-5-hydroxy-4,5-dihydrooxepino[3',4':6,7]indolizino[1,2-b]quinoline-3,15(1H,13H)-dione
CAS Number
PubChem CID
ChemSpider
UNII
ChEBI
ChEMBL
Chemical and physical data
FormulaC21H16F2N2O4
Molar mass398.366 g·mol−1
3D model (JSmol)
  • O=C1N2C(C3=NC(C=C(F)C(F)=C4)=C4C=C3C2)=CC([C@@](O)(CC)C5)=C1COC5=O
  • InChI=1S/C21H16F2N2O4/c1-2-21(28)7-18(26)29-9-12-13(21)5-17-19-11(8-25(17)20(12)27)3-10-4-14(22)15(23)6-16(10)24-19/h3-6,28H,2,7-9H2,1H3/t21-/m1/s1
  • Key:LFQCJSBXBZRMTN-OAQYLSRUSA-N

Diflomotecan (also known as BN80905) is a chemotherapeutic agent that is a topoisomerase inhibitor (Top1). It varies from other camptothecin based Top1 inhibitors like topotecan in having a 7-membered E-ring. The oxepan-2-one ring in the homocamptothecin analogues is more stable in plasma compared to the 6-membered lactone in camptothecin.[1] Diflomotecan was the first homocamptothecin to enter clinical trials[2] and is currently in phase I for treating patients with sensitive small cell lung cancer (SCLC).[3]

References[edit]

  1. ^ Bailly C (2003). "Homocamptothecins: potent topoisomerase I inhibitors and promising anticancer drugs". Critical Reviews in Oncology/Hematology. 45: 91–108. doi:10.1016/s1040-8428(02)00090-2.
  2. ^ Kroep JR, Gelderblom H (2009). "Diflomotecan, a promising homocamptothecin for cancer therapy". Expert Opin Investig Drugs. 18: 69–75. doi:10.1517/13543780802571674.
  3. ^ "Diflomotecan (BN80915) Administered Once Every 3 Weeks in Treating Patients With Sensitive Small Cell Lung Cancer (SCLC) - Full Text View - ClinicalTrials.gov". clinicaltrials.gov.